Company intelligence / Profile preview

Timberline

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company advancing CM313, an IgG1 monoclonal antibody targeting CD38 with enhanced complement-dependent cytotoxicity. CM313 has been clinically studied in immune thrombocytopenic purpura, systemic lupus erythematosus, and relapsed/refractory multiple myeloma and has shown potentially best-in-class activity, including a 95% response rate in treatment-refractory immune thrombocytopenia reported in a New England Journal of Medicine study.[1][2][3]

Therapeutic areas: HematologyImmunologyOncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Keymed BiosciencesMountainfield Venture Partners

Beyond the preview

Go deeper on Timberline.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Timberline.

Explore the full profile